Access Pharma’s Drug Delivery Technology Is a Stealth Asset
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
oral mucositis
Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
OneMedPlace Interviews Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently sat down with Jeffrey Davis, CEO of Access Pharmaceuticals, to discuss the clinical success of MuGard and the latest news surrounding the product’s launch.
MuGard: Potential Blockbuster for Oral Mucositis Prevention Market
Oral mucositis is a nearly inevitable complication for patients undergoing chemotherapy or radiation treatment for head or neck cancer.